Brivaracetam vs Levetiracetam (Elepsia XR)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Epilepsy

Shared mechanism: Synaptic vesicle glycoprotein 2A (SV2A) · full Epilepsy pipeline

Brivaracetam

Marketed by UCB

Approved in Epilepsysmall molecule
Partial signal

NCT04666610 · Phase 3 · completed

The trial randomized 154 participants and used quadruple masking with placebo control, with absence-seizure freedom measured by 24-hour EEG as the primary clinical endpoint. Because the registry has no posted results, whether the primary endpoint was met is unknown, supporting a moderate evidence grade rather than a strong one.

Next expected readout: November 2029 · NCT06315322 (registry estimate)

No aligned efficacy figure on record for this race.

Levetiracetam (Elepsia XR)

Rights held by Sun Pharma Advanced Research Company Limited and partners; US product discontinued

Approved in Epilepsysmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Epilepsy

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBrivaracetamLevetiracetam (Elepsia XR)
Seizure frequency, % change-53.0% vs -24.4%−28.7 vs placebo50 mg/day · wk 7 · n 52NCT00175825
2 other results
  • -41.6% vs -24.4% 20 mg/day · wk 7 · n 52 · Phase 2 · secondary NCT00175825
  • -29.9% vs -24.4% 5 mg/day · wk 7 · n 50 · Phase 2 · secondary NCT00175825
—Not posted · NCT05722951
50% responder rate36% vs 20%+16 vs placebo100 mg/day · wk 12 · n 100NCT00490035
7 other results
  • 49.3% vs 19% 200 mg/Day · wk 12 · n 148 · Phase 3 · secondary NCT03083665
  • 41.1% vs 19% 50 mg/Day · wk 12 · n 151 · Phase 3 · secondary NCT03083665
  • 27.3% vs 20% 50 mg/day · wk 12 · n 99 · Phase 3 · secondary NCT00490035
  • 27.3% vs 20% 20 mg/day · wk 12 · n 99 · Phase 3 · secondary NCT00490035
  • 55.8% vs 16.7% 50 mg/day · wk 7 · n 52 · Phase 2 · secondary NCT00175825
  • 44.2% vs 16.7% 20 mg/day · wk 7 · n 52 · Phase 2 · secondary NCT00175825
  • 32% vs 16.7% 5 mg/day · wk 7 · n 50 · Phase 2 · secondary NCT00175825
—Not posted · NCT05722951
Seizure freedom86.7% vs 73.3%vs Lorazepam (LZP)100 mg · n 15NCT03021018
5 other results
  • 80% vs 73.3% 100 mg · n 15 · Phase 2 · secondary NCT03021018
  • 80% vs 60% 100 mg · n 15 · Phase 2 · secondary NCT03021018
  • 80% vs 73.3% 200 mg · n 15 · Phase 2 · secondary NCT03021018
  • 80% vs 73.3% 200 mg · n 15 · Phase 2 · secondary NCT03021018
  • 80% vs 60% 200 mg · n 15 · Phase 2 · secondary NCT03021018
—Not posted · NCT05722951

Seizure frequency, % change

Brivaracetam
-53.0% vs -24.4%−28.7 vs placebo50 mg/day · wk 7 · n 52NCT00175825
2 other results
  • -41.6% vs -24.4% 20 mg/day · wk 7 · n 52 · Phase 2 · secondary NCT00175825
  • -29.9% vs -24.4% 5 mg/day · wk 7 · n 50 · Phase 2 · secondary NCT00175825
Levetiracetam (Elepsia XR)
—Not posted · NCT05722951

50% responder rate

Brivaracetam
36% vs 20%+16 vs placebo100 mg/day · wk 12 · n 100NCT00490035
7 other results
  • 49.3% vs 19% 200 mg/Day · wk 12 · n 148 · Phase 3 · secondary NCT03083665
  • 41.1% vs 19% 50 mg/Day · wk 12 · n 151 · Phase 3 · secondary NCT03083665
  • 27.3% vs 20% 50 mg/day · wk 12 · n 99 · Phase 3 · secondary NCT00490035
  • 27.3% vs 20% 20 mg/day · wk 12 · n 99 · Phase 3 · secondary NCT00490035
  • 55.8% vs 16.7% 50 mg/day · wk 7 · n 52 · Phase 2 · secondary NCT00175825
  • 44.2% vs 16.7% 20 mg/day · wk 7 · n 52 · Phase 2 · secondary NCT00175825
  • 32% vs 16.7% 5 mg/day · wk 7 · n 50 · Phase 2 · secondary NCT00175825
Levetiracetam (Elepsia XR)
—Not posted · NCT05722951

Seizure freedom

Brivaracetam
86.7% vs 73.3%vs Lorazepam (LZP)100 mg · n 15NCT03021018
5 other results
  • 80% vs 73.3% 100 mg · n 15 · Phase 2 · secondary NCT03021018
  • 80% vs 60% 100 mg · n 15 · Phase 2 · secondary NCT03021018
  • 80% vs 73.3% 200 mg · n 15 · Phase 2 · secondary NCT03021018
  • 80% vs 73.3% 200 mg · n 15 · Phase 2 · secondary NCT03021018
  • 80% vs 60% 200 mg · n 15 · Phase 2 · secondary NCT03021018
Levetiracetam (Elepsia XR)
—Not posted · NCT05722951
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Levetiracetam (Elepsia XR): registry results are on file for Epilepsy, but their comparison mappings are not yet available.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Brivaracetam: 4 of 4 rows · Levetiracetam (Elepsia XR): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBrivaracetam
Dropout rate
21.9%Childhood Absence Epilepsy (CAE): a
NCT05109234 · Phase 3 · registry result, not featured evidence
show 40 more results
30%Juvenile Absence Epilepsy (JAE): B
NCT05109234 · Phase 3 · registry result, not featured evidence
41.2%Direct Enrollers BRV
NCT03250377 · Phase 3 · registry result, not featured evidence
42.9%N01379 BRV
NCT03250377 · Phase 3 · registry result, not featured evidence
5.4%200 mg/Day
NCT03083665 · Phase 3 · registry result, not featured evidence
—200 mg/Day
NCT03083665 · Phase 3 · registry result, not featured evidence
3.3%50 mg/Day
NCT03083665 · Phase 3 · registry result, not featured evidence
—50 mg/Day
NCT03083665 · Phase 3 · registry result, not featured evidence
50%Age Cohort: ≥1 Month to <2 Years
NCT01364597 · Phase 3 · registry result, not featured evidence
43.1%Age Cohort: ≥12 to <17 Years
NCT01364597 · Phase 3 · registry result, not featured evidence
73.3%Age Cohort: ≥2 to <4 Years
NCT01364597 · Phase 3 · registry result, not featured evidence
53.9%Age Cohort: ≥4 to <12 Years
NCT01364597 · Phase 3 · registry result, not featured evidence
—
NCT00175916 · Phase 3 · registry result, not featured evidence
—
NCT01339559 · Phase 3 · registry result, not featured evidence
74.4%
NCT00150800 · Phase 3 · registry result, not featured evidence
—
NCT00761774 · Phase 3 · registry result, not featured evidence
—Brivaracetam Focal Epilepsy (SS)
NCT01728077 · Phase 3 · registry result, not featured evidence
—Brivaracetam Generalized Epilepsy
NCT01728077 · Phase 3 · registry result, not featured evidence
11.4%100 mg/day
NCT01261325 · Phase 3 · registry result, not featured evidence
10.4%200 mg/day
NCT01261325 · Phase 3 · registry result, not featured evidence
10.3%
NCT01653262 · Phase 3 · registry result, not featured evidence
0%Brivaracetam (BRV) Tablets / BRV B
NCT01405508 · Phase 3 · registry result, not featured evidence
0%Brivaracetam (BRV) Tablets / BRV I
NCT01405508 · Phase 3 · registry result, not featured evidence
6%100 mg/day
NCT00490035 · Phase 3 · registry result, not featured evidence
12%50 mg/day
NCT00490035 · Phase 3 · registry result, not featured evidence
6.1%20 mg/day
NCT00490035 · Phase 3 · registry result, not featured evidence
8.8%50 mg/day
NCT00464269 · Phase 3 · registry result, not featured evidence
7%20 mg/day
NCT00464269 · Phase 3 · registry result, not featured evidence
17.2%5 mg/day
NCT00464269 · Phase 3 · registry result, not featured evidence
10%
NCT00504881 · Phase 3 · registry result, not featured evidence
—Age Cohort: >=1 Month to <2 Years
NCT03405714 · Phase 2 · registry result, not featured evidence
—Age Cohort: >=12 to <16 Years (SS-
NCT03405714 · Phase 2 · registry result, not featured evidence
—Age Cohort: >=2 to <6 Years (SS-iv
NCT03405714 · Phase 2 · registry result, not featured evidence
—Age Cohort: >=6 to <12 Years (SS-i
NCT03405714 · Phase 2 · registry result, not featured evidence
—100 mg
NCT03021018 · Phase 2 · registry result, not featured evidence
—200 mg
NCT03021018 · Phase 2 · registry result, not featured evidence
—
NCT00422422 · Phase 2 · registry result, not featured evidence
1.9%50 mg/day
NCT00175825 · Phase 2 · registry result, not featured evidence
1.9%20 mg/day
NCT00175825 · Phase 2 · registry result, not featured evidence
8%5 mg/day
NCT00175825 · Phase 2 · registry result, not featured evidence
—
NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy
Discontinued due to AEs
3.1%Childhood Absence Epilepsy (CAE): a
NCT05109234 · Phase 3 · registry result, not featured evidence
show 40 more results
10%Juvenile Absence Epilepsy (JAE): B
NCT05109234 · Phase 3 · registry result, not featured evidence
11.8%Direct Enrollers BRV
NCT03250377 · Phase 3 · registry result, not featured evidence
0%N01379 BRV
NCT03250377 · Phase 3 · registry result, not featured evidence
3.4%200 mg/Day
NCT03083665 · Phase 3 · registry result, not featured evidence
—200 mg/Day
NCT03083665 · Phase 3 · registry result, not featured evidence
2.6%50 mg/Day
NCT03083665 · Phase 3 · registry result, not featured evidence
—50 mg/Day
NCT03083665 · Phase 3 · registry result, not featured evidence
11.1%Age Cohort: ≥1 Month to <2 Years
NCT01364597 · Phase 3 · registry result, not featured evidence
10.8%Age Cohort: ≥12 to <17 Years
NCT01364597 · Phase 3 · registry result, not featured evidence
33.3%Age Cohort: ≥2 to <4 Years
NCT01364597 · Phase 3 · registry result, not featured evidence
11.3%Age Cohort: ≥4 to <12 Years
NCT01364597 · Phase 3 · registry result, not featured evidence
—
NCT00175916 · Phase 3 · registry result, not featured evidence
—
NCT01339559 · Phase 3 · registry result, not featured evidence
13.3%
NCT00150800 · Phase 3 · registry result, not featured evidence
—
NCT00761774 · Phase 3 · registry result, not featured evidence
—Brivaracetam Focal Epilepsy (SS)
NCT01728077 · Phase 3 · registry result, not featured evidence
—Brivaracetam Generalized Epilepsy
NCT01728077 · Phase 3 · registry result, not featured evidence
—100 mg/day
NCT01261325 · Phase 3 · registry result, not featured evidence
—200 mg/day
NCT01261325 · Phase 3 · registry result, not featured evidence
—
NCT01653262 · Phase 3 · registry result, not featured evidence
—Brivaracetam (BRV) Tablets / BRV B
NCT01405508 · Phase 3 · registry result, not featured evidence
—Brivaracetam (BRV) Tablets / BRV I
NCT01405508 · Phase 3 · registry result, not featured evidence
0%100 mg/day
NCT00490035 · Phase 3 · registry result, not featured evidence
1%50 mg/day
NCT00490035 · Phase 3 · registry result, not featured evidence
0%20 mg/day
NCT00490035 · Phase 3 · registry result, not featured evidence
—50 mg/day
NCT00464269 · Phase 3 · registry result, not featured evidence
—20 mg/day
NCT00464269 · Phase 3 · registry result, not featured evidence
—5 mg/day
NCT00464269 · Phase 3 · registry result, not featured evidence
—
NCT00504881 · Phase 3 · registry result, not featured evidence
—Age Cohort: >=1 Month to <2 Years
NCT03405714 · Phase 2 · registry result, not featured evidence
—Age Cohort: >=12 to <16 Years (SS-
NCT03405714 · Phase 2 · registry result, not featured evidence
—Age Cohort: >=2 to <6 Years (SS-iv
NCT03405714 · Phase 2 · registry result, not featured evidence
—Age Cohort: >=6 to <12 Years (SS-i
NCT03405714 · Phase 2 · registry result, not featured evidence
—100 mg
NCT03021018 · Phase 2 · registry result, not featured evidence
—200 mg
NCT03021018 · Phase 2 · registry result, not featured evidence
—
NCT00422422 · Phase 2 · registry result, not featured evidence
1.9%50 mg/day
NCT00175825 · Phase 2 · registry result, not featured evidence
1.9%20 mg/day
NCT00175825 · Phase 2 · registry result, not featured evidence
4%5 mg/day
NCT00175825 · Phase 2 · registry result, not featured evidence
—
NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy
Serious AEs
3.1%Childhood Absence Epilepsy (CAE): a
NCT05109234 · Phase 3 · registry result, not featured evidence
show 40 more results
10%Juvenile Absence Epilepsy (JAE): B
NCT05109234 · Phase 3 · registry result, not featured evidence
17.6%Direct Enrollers BRV
NCT03250377 · Phase 3 · registry result, not featured evidence
71.4%N01379 BRV
NCT03250377 · Phase 3 · registry result, not featured evidence
2.7%200 mg/Day
NCT03083665 · Phase 3 · registry result, not featured evidence
2.7%200 mg/Day
NCT03083665 · Phase 3 · registry result, not featured evidence
1.3%50 mg/Day
NCT03083665 · Phase 3 · registry result, not featured evidence
0%50 mg/Day
NCT03083665 · Phase 3 · registry result, not featured evidence
38.9%Age Cohort: ≥1 Month to <2 Years
NCT01364597 · Phase 3 · registry result, not featured evidence
29.2%Age Cohort: ≥12 to <17 Years
NCT01364597 · Phase 3 · registry result, not featured evidence
53.3%Age Cohort: ≥2 to <4 Years
NCT01364597 · Phase 3 · registry result, not featured evidence
29.8%Age Cohort: ≥4 to <12 Years
NCT01364597 · Phase 3 · registry result, not featured evidence
29.1%
NCT00175916 · Phase 3 · registry result, not featured evidence
18.3%
NCT01339559 · Phase 3 · registry result, not featured evidence
22.8%
NCT00150800 · Phase 3 · registry result, not featured evidence
24.1%
NCT00761774 · Phase 3 · registry result, not featured evidence
26.3%Brivaracetam Focal Epilepsy (SS)
NCT01728077 · Phase 3 · registry result, not featured evidence
28.6%Brivaracetam Generalized Epilepsy
NCT01728077 · Phase 3 · registry result, not featured evidence
3.2%100 mg/day
NCT01261325 · Phase 3 · registry result, not featured evidence
3.2%200 mg/day
NCT01261325 · Phase 3 · registry result, not featured evidence
3.4%
NCT01653262 · Phase 3 · registry result, not featured evidence
0%Brivaracetam (BRV) Tablets / BRV B
NCT01405508 · Phase 3 · registry result, not featured evidence
0%Brivaracetam (BRV) Tablets / BRV I
NCT01405508 · Phase 3 · registry result, not featured evidence
2%100 mg/day
NCT00490035 · Phase 3 · registry result, not featured evidence
4%50 mg/day
NCT00490035 · Phase 3 · registry result, not featured evidence
2%20 mg/day
NCT00490035 · Phase 3 · registry result, not featured evidence
4%50 mg/day
NCT00464269 · Phase 3 · registry result, not featured evidence
3%20 mg/day
NCT00464269 · Phase 3 · registry result, not featured evidence
1%5 mg/day
NCT00464269 · Phase 3 · registry result, not featured evidence
5.6%
NCT00504881 · Phase 3 · registry result, not featured evidence
7.7%Age Cohort: >=1 Month to <2 Years
NCT03405714 · Phase 2 · registry result, not featured evidence
0%Age Cohort: >=12 to <16 Years (SS-
NCT03405714 · Phase 2 · registry result, not featured evidence
0%Age Cohort: >=2 to <6 Years (SS-iv
NCT03405714 · Phase 2 · registry result, not featured evidence
0%Age Cohort: >=6 to <12 Years (SS-i
NCT03405714 · Phase 2 · registry result, not featured evidence
0%100 mg
NCT03021018 · Phase 2 · registry result, not featured evidence
0%200 mg
NCT03021018 · Phase 2 · registry result, not featured evidence
8.1%
NCT00422422 · Phase 2 · registry result, not featured evidence
0%50 mg/day
NCT00175825 · Phase 2 · registry result, not featured evidence
1.9%20 mg/day
NCT00175825 · Phase 2 · registry result, not featured evidence
0%5 mg/day
NCT00175825 · Phase 2 · registry result, not featured evidence
0%
NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy
Most frequent reported AEs
a
petit mal epilepsy 14.1%
pyrexia 6.3%
headache 4.7%
NCT05109234 · Phase 3 · registry result, not featured evidence
show 40 more results
petit mal epilepsy 25%
pyrexia 20%
headache 10%
NCT05109234 · Phase 3 · registry result, not featured evidence
corona virus infection 32.4% (placebo 24.1%)
nasopharyngitis 26.5% (placebo 37%)
pyrexia 17.6% (placebo 16.7%)
NCT03250377 · Phase 3 · registry result, not featured evidence
dizziness 42.9% (placebo 22.2%)
nasopharyngitis 42.9% (placebo 37%)
abdominal pain upper 28.6% (placebo 3.7%)
NCT03250377 · Phase 3 · registry result, not featured evidence
200 mg/Day
somnolence 18.9% (placebo 8.1%)
dizziness 14.2% (placebo 4%)
nasopharyngitis 6.8% (placebo 6.7%)
NCT03083665 · Phase 3 · registry result, not featured evidence
200 mg/Day
nasopharyngitis 5.4% (placebo 6.7%)
dizziness 0% (placebo 4%)
headache 0% (placebo 7.4%)
NCT03083665 · Phase 3 · registry result, not featured evidence
50 mg/Day
dizziness 11.3% (placebo 4%)
somnolence 9.9% (placebo 8.1%)
headache 7.3% (placebo 7.4%)
NCT03083665 · Phase 3 · registry result, not featured evidence
50 mg/Day
nasopharyngitis 5.9% (placebo 6.7%)
dizziness 0% (placebo 4%)
headache 0% (placebo 7.4%)
NCT03083665 · Phase 3 · registry result, not featured evidence
pyrexia 41.7%
nasopharyngitis 30.6%
vomiting 30.6%
NCT01364597 · Phase 3 · registry result, not featured evidence
headache 24.6%
nasopharyngitis 24.6%
seizure 16.9%
NCT01364597 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 33.3%
vomiting 33.3%
nasopharyngitis 26.7%
NCT01364597 · Phase 3 · registry result, not featured evidence
nasopharyngitis 31.2%
pharyngitis 27.7%
pyrexia 26.2%
NCT01364597 · Phase 3 · registry result, not featured evidence
headache 21.8%
nasopharyngitis 18.4%
dizziness 14.4%
NCT00175916 · Phase 3 · registry result, not featured evidence
headache 13.3%
dizziness 13.1%
somnolence 9.5%
NCT01339559 · Phase 3 · registry result, not featured evidence
headache 24.7%
dizziness 21.3%
nasopharyngitis 14.1%
NCT00150800 · Phase 3 · registry result, not featured evidence
nasopharyngitis 17.6%
depression 16.7%
convulsion 15.7%
NCT00761774 · Phase 3 · registry result, not featured evidence
headache 36.8%
back pain 15.8%
convulsion 15.8%
NCT01728077 · Phase 3 · registry result, not featured evidence
upper respiratory tract 28.6%
urinary tract infection 28.6%
back pain 14.3%
NCT01728077 · Phase 3 · registry result, not featured evidence
100 mg/day
somnolence 19.4% (placebo 7.7%)
dizziness 10.3% (placebo 5%)
fatigue 7.5% (placebo 3.8%)
NCT01261325 · Phase 3 · registry result, not featured evidence
200 mg/day
somnolence 16.8% (placebo 7.7%)
dizziness 14.4% (placebo 5%)
fatigue 11.6% (placebo 3.8%)
NCT01261325 · Phase 3 · registry result, not featured evidence
headache 17.2%
back pain 10.3%
fatigue 10.3%
NCT01653262 · Phase 3 · registry result, not featured evidence
somnolence 25.9% (placebo 30.8%)
dizziness 11.1% (placebo 15.4%)
fatigue 11.1% (placebo 3.8%)
NCT01405508 · Phase 3 · registry result, not featured evidence
somnolence 34.6% (placebo 30.8%)
dizziness 15.4% (placebo 15.4%)
headache 7.7% (placebo 7.7%)
NCT01405508 · Phase 3 · registry result, not featured evidence
100 mg/day
headache 9% (placebo 10%)
fatigue 8% (placebo 2%)
somnolence 8% (placebo 6%)
NCT00490035 · Phase 3 · registry result, not featured evidence
50 mg/day
headache 18.2% (placebo 10%)
dizziness 7.1% (placebo 5%)
somnolence 6.1% (placebo 6%)
NCT00490035 · Phase 3 · registry result, not featured evidence
20 mg/day
headache 14.1% (placebo 10%)
nasopharyngitis 8.1% (placebo 1%)
somnolence 8.1% (placebo 6%)
NCT00490035 · Phase 3 · registry result, not featured evidence
50 mg/day
somnolence 16.8% (placebo 7.1%)
dizziness 15.8% (placebo 9.2%)
headache 12.9% (placebo 14.3%)
NCT00464269 · Phase 3 · registry result, not featured evidence
20 mg/day
dizziness 14% (placebo 9.2%)
somnolence 14% (placebo 7.1%)
fatigue 13% (placebo 2%)
NCT00464269 · Phase 3 · registry result, not featured evidence
5 mg/day
somnolence 14.4% (placebo 7.1%)
dizziness 12.4% (placebo 9.2%)
headache 11.3% (placebo 14.3%)
NCT00464269 · Phase 3 · registry result, not featured evidence
headache 14.5% (placebo 19.8%)
somnolence 11.1% (placebo 4.1%)
dizziness 8.6% (placebo 5.8%)
NCT00504881 · Phase 3 · registry result, not featured evidence
somnolence 7.7%
upper respiratory tract infection 7.7%
aggression 0%
NCT03405714 · Phase 2 · registry result, not featured evidence
dizziness 16.7%
pharyngitis 8.3%
aggression 0%
NCT03405714 · Phase 2 · registry result, not featured evidence
ear infection 15.4%
pyrexia 15.4%
somnolence 15.4%
NCT03405714 · Phase 2 · registry result, not featured evidence
fatigue 8.3%
insomnia 8.3%
pruritus 8.3%
NCT03405714 · Phase 2 · registry result, not featured evidence
100 mg
dizziness 20%
headache 13.3%
nausea 13.3%
NCT03021018 · Phase 2 · registry result, not featured evidence
200 mg
nausea 13.3%
dizziness 6.7%
gamma-glutamyltransferase increased 6.7%
NCT03021018 · Phase 2 · registry result, not featured evidence
irritability 8.1%
somnolence 8.1%
decreased appetite 7.1%
NCT00422422 · Phase 2 · registry result, not featured evidence
50 mg/day
dizziness 7.7% (placebo 5.6%)
fatigue 5.8% (placebo 3.7%)
somnolence 5.8% (placebo 7.4%)
NCT00175825 · Phase 2 · registry result, not featured evidence
20 mg/day
somnolence 5.8% (placebo 7.4%)
fatigue 3.8% (placebo 3.7%)
headache 3.8% (placebo 7.4%)
NCT00175825 · Phase 2 · registry result, not featured evidence
5 mg/day
headache 8% (placebo 7.4%)
influenza 8% (placebo 7.4%)
neutropenia 8% (placebo 1.9%)
NCT00175825 · Phase 2 · registry result, not featured evidence
somnolence 80%
dizziness 66.7%
headache 60%
NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Brivaracetam

Absence Seizure Free 46.4% (n=56) @ 26wk
responder rate · % of participants
No placebo or comparator arm
NCT05109234 · Phase 3 · registry result, not featured evidence
show 21 more results
70% (n=20) @ 26wk
NCT05109234 · Phase 3 · registry result, not featured evidence
42.6% (n=56) @ 52wk
NCT05109234 · Phase 3 · registry result, not featured evidence
44.4% (n=20) @ 52wk
NCT05109234 · Phase 3 · registry result, not featured evidence
38.9% (n=56) @ 78wk
NCT05109234 · Phase 3 · registry result, not featured evidence
50% (n=20) @ 78wk
NCT05109234 · Phase 3 · registry result, not featured evidence
26.7% (n=56) @ 104wk
NCT05109234 · Phase 3 · registry result, not featured evidence
18.2% (n=20) @ 104wk
NCT05109234 · Phase 3 · registry result, not featured evidence
34.4% (n=64) @ 13wk
NCT05109234 · Phase 3 · registry result, not featured evidence
35% (n=20) @ 13wk
NCT05109234 · Phase 3 · registry result, not featured evidence
39% (n=64) @ 26wk
NCT05109234 · Phase 3 · registry result, not featured evidence
55% (n=20) @ 26wk
NCT05109234 · Phase 3 · registry result, not featured evidence
37.7% (n=64) @ 39wk
NCT05109234 · Phase 3 · registry result, not featured evidence
57.9% (n=20) @ 39wk
NCT05109234 · Phase 3 · registry result, not featured evidence
38.8% (n=64) @ 52wk
NCT05109234 · Phase 3 · registry result, not featured evidence
55.6% (n=20) @ 52wk
NCT05109234 · Phase 3 · registry result, not featured evidence
31.8% (n=64) @ 65wk
NCT05109234 · Phase 3 · registry result, not featured evidence
61.1% (n=20) @ 65wk
NCT05109234 · Phase 3 · registry result, not featured evidence
35.9% (n=64) @ 78wk
NCT05109234 · Phase 3 · registry result, not featured evidence
56.3% (n=20) @ 78wk
NCT05109234 · Phase 3 · registry result, not featured evidence
30.3% (n=64) @ 91wk
NCT05109234 · Phase 3 · registry result, not featured evidence
42.9% (n=20) @ 91wk
NCT05109234 · Phase 3 · registry result, not featured evidence
Partial Seizure Frequency 67% (n=7) vs 60.6% (n=54) placebo
percent change · % of baseline
NCT03250377 · Phase 3 · registry result, not featured evidence
Partial Seizure 57.1% (n=7) vs 66.7% (n=54) placebo
responder rate · % of participants
NCT03250377 · Phase 3 · registry result, not featured evidence
Partial Seizure Frequency -32.6% (n=34)
percent change · % of baseline
No placebo or comparator arm
NCT03250377 · Phase 3 · registry result, not featured evidence
Partial Seizure 26.5% (n=34)
responder rate · % of participants
No placebo or comparator arm
NCT03250377 · Phase 3 · registry result, not featured evidence
Seizure Free 6 28.6% (n=7) vs 15.4% (n=52) placebo
responder rate · % of participants
NCT03250377 · Phase 3 · registry result, not featured evidence
Seizure Free 12 33.3% (n=6) vs 8.3% (n=48) placebo
responder rate · % of participants
NCT03250377 · Phase 3 · registry result, not featured evidence
Continuous Seizure Free 14.3% (n=7) vs 1.9% (n=54) placebo
responder rate · % of participants
Participants with all-type seizure-freedom
NCT03250377 · Phase 3 · registry result, not featured evidence
Seizure Free 6 24.1% (n=29)
responder rate · % of participants
No placebo or comparator arm
NCT03250377 · Phase 3 · registry result, not featured evidence
Seizure Free 12 15.4% (n=26)
responder rate · % of participants
No placebo or comparator arm
NCT03250377 · Phase 3 · registry result, not featured evidence
Continuous Seizure Free 5.9% (n=34)
responder rate · % of participants
No placebo or comparator arm
Participants with all-type seizure-freedom
NCT03250377 · Phase 3 · registry result, not featured evidence
Partial Onset Seizure Frequency Per 28d 4.19 vs 7.17 placebo per 28 day @ 12wk200 mg/Day
absolute value · per 28 day
NCT03083665 · Phase 3 · registry result, not featured evidence
show 1 more result
5.93 vs 7.17 placebo per 28 day @ 12wk50 mg/Day
NCT03083665 · Phase 3 · registry result, not featured evidence

+ 34 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Brivaracetam's landscape · Levetiracetam (Elepsia XR)'s landscape